Newfin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 29 Year, 22 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
- Revenue Growth -25.37%
- Profit Growth -1485.30%
- Ebitda -117.38%
- Net Worth -5.17%
- Total Assets -30.74%
About Newfin Pharmaceuticals
Newfin Pharmaceuticals Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 January 1996 and has a history of 29 years. Its registered office is in Kukatpally, Hyderabad, Telangana.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹3.00 M.
Suresh Adapa and Tamma Rani serve as directors at the Company.
Company Details
-
LocationKukatpally, Hyderabad, Telangana
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24239TG1996PTC022898
-
Company No.
022898
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jan 1996
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Newfin Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Adapa
|
Additional Director | 25-Aug-2015 | Current |
|
Tamma Rani
|
Additional Director | 01-Jul-2016 | Current |
Financial Performance of Newfin Pharmaceuticals.
Newfin Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 25.37% decrease. The company also saw a substantial fall in profitability, with a 1485.3% decrease in profit. The company's net worth dipped by a decrease of 5.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Newfin Pharmaceuticals?
In 2017, Newfin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aushadi Health Care Private LimitedSuresh Adapa is a mutual person
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Sbi : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jul 2003 | Sbi | ₹1.00 M | Open |
| 02 Dec 1996 | Sbi | ₹2.00 M | Open |
How Many Employees Work at Newfin Pharmaceuticals?
Unlock and access historical data on people associated with Newfin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Newfin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Newfin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
